Quote:
Originally Posted by Chris
The lateness of the EU’s commitment to signing contracts is of material interest though, because it means all the production facilities set up to fulfil EU orders are months behind those in the UK at getting set up and learning how to maximise yield. Clearly that’s not the only problem they’re having but it hasn’t helped. At the Dutch plant in question there may simply be a lack of experience in the necessary techniques required to get the bio-reactors to their optimum performance. We know that the industrial-scale process AstraZeneca developed from the Oxford “recipe” works because we have two locations in the UK churning it out in large quantities.
|
Timeliness is not in dispute, I reiterate that I agree on this point.
Seph was arguing that the EU had been at fault by:
1) Signing a contract when it knew it could not be fufilled.
2) Not mitigating the risks by signing contracts with other suppliers like Pfizer.
Both of these statements are wrong.